In the present study, we analysed the role of ACE2 in breast cancer prognosis using databases and human tissues, verified the anti-angiogenetic effects of ACE2 in vitro and in vivo and then revealed the VEGFa/VEGFR2/ERK pathway. This evidence concerns the gene MAPK1 and breast cancer.